ABBV AbbVie Inc

   By Stephen Nakrosis 
 

AbbVie Canada on Wednesday said psoriasis treatment Skyrizi is now listed for public payer coverage across Canada, following its addition as a special authorization drug on the formulary of Prince Edward Island.

Skyrizi, or risankizumab, is a prescription medicine used to treat adults with moderate to severe plaque psoriasis and is part of a collaboration between Boehringer Ingelheim and AbbVie, AbbVie Canada said.

The company also said psoriasis affects 1 million Canadians and 125 million people around the world.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

February 24, 2021 11:47 ET (16:47 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.